Semnur Pharmaceuticals, Inc.

Semnur Pharmaceuticals, Inc., trading under the ticker DECA, is a clinical-stage biopharmaceutical company that entered the public markets through a de-SPAC merger with Denali Capital Acquisition Corp., a blank-check company sponsored by Denali Capital Group that completed its IPO in 2021. The company operates in the healthcare and life sciences sector, with a pipeline focused on non-opioid pain management therapeutics. The annual report on Form 10-K filed April 1, 2024, under accession number 0001213900-24-028809, reflects the company's post-merger operating status as a publicly traded entity. For complete filing history, sponsor details, and deal analytics on DECA and hundreds of other SPAC transactions, sign up for full data access at SpacDesk.